波士顿咨询（BCG）：2026效率之后中国医药创新的价值攀登研究报告（英文版）（30页）.pdf

1、Beyond Efficiency:Chinas Next Leap in Biopharma InnovationApril 2026 By Chun Wu,Qicong Hu,Jing Du,Lulu Chao,and Cliff Hu01 Introduction02 Chinas New Global Stance in Biopharma Innovation and Its Next-Decade TrajectoryChinas New Global StanceCritical Variables for the Next Leap15 The Resilience and S

2、trength of Chinas Biopharma Innovation EcosystemCapital ResilienceTalent SustainabilityAcademia-Industry Translation System24 The Road Ahead26 About the AuthorsContentsBEYOND EFFICIENCY:CHINAS NEXT LEAP IN BIOPHARMA INNOVATION 1Over the past decade,Chinas biopharma innovation has undergone a deep an

3、d systemic“efficiency revolution,”centered on a reshaping of system capabilities defined by scale,speed,and cost.As regulatory rules have progressively aligned with international standards,and as capital,talent,and the academia-industry ecosystem have rapidly coalesced,China has moved from being a f

4、ollower on the margins of the global innovation system into an increasingly influential innovation hub.This accumulation of capabilities has elevated China into the forefront of global biopharma innovation.Looking to the next decade,Chinas biopharma innovation stands at a new inflection point.The ke

5、y question is whether efficiency gains can be translated into globally recognized innovation valuewith the accompanying price tag.Moving from efficiency advantage to value leadership means shifting from an innovation model defined by efficiency to one defined by quality,originality,system maturity,a

6、nd long-term sustainability.This transition will materially reshape Chinas role in the global innovation system and redefine its trajectory over the next decade.As Chinas biopharma innovation enters a phase marked by accelerating breakthroughs,deepening validation,and expanding global recognition,BC